Identifying tumor antigens in endocrine malignancies

Trends in Endocrinology and Metabolism

Volumn 20, Issue 3, 2009, Pages 122-129

  Wuttke, Margret ^a   Papewalis, Claudia ^a   Jacobs, Benedikt ^a   Schott, Matthias ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; DENDRITIC CELL VACCINE; EPITHELIAL CELL ADHESION MOLECULE; MELANOMA ANTIGEN 3; MUCIN 1; NY ESO 1 ANTIGEN; PARATHYROID HORMONE; STEROIDOGENIC ACUTE REGULATORY PROTEIN; SURVIVIN; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR CDX2; TUMOR ANTIGEN; VESICULAR MONOAMINE TRANSPORTER 1;

ANTIGEN FUNCTION; ANTIGEN SPECIFICITY; CANCER IMMUNIZATION; DENDRITIC CELL; DRUG TARGETING; ENDOCRINE TUMOR; GENE OVEREXPRESSION; HUMAN; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR ESCAPE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNE DISEASES; ENDOCRINE SYSTEM DISEASES; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; NEOPLASMS; PEPTIDE HORMONES; VACCINATION;

EID: 62649111669     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2008.12.003     Document Type: Review

References (60)

1. Ouyang W., et al. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28 (2008) 454-467
2. Zhu J., and Paul W.E. CD4 T cells: fates, functions, and faults 3. Blood 112 (2008) 1557-1569
3. Berard F., et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192 (2000) 1535-1544
4. + T-helper and a T-killer cell. Nature 393 (1998) 474-478
5. Rabinovich G.A., et al. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25 (2007) 267-296
6. Zitvogel L., et al. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 (2006) 715-727
7. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6 (2006) 295-307
8. Molenkamp B.G., et al. Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option. Immunobiology 211 (2006) 651-661
9. + T cells against NY-ESO-1. N. Engl. J. Med. 358 (2008) 2698-2703
10. Zhang L., et al. Insulin as an autoantigen in NOD/human diabetes. Curr. Opin. Immunol. 20 (2008) 111-118
11. Wong F.S., et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library 1. Nat. Med. 5 (1999) 1026-1031
12. Nakayama M., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435 (2005) 220-223
13. Fife B.T., et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203 (2006) 2737-2747
14. Jaeckel E., et al. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat. Immunol. 5 (2004) 1028-1035
15. Seissler J., et al. Mapping of novel autoreactive epitopes of the diabetes-associated autoantigen IA-2. Clin. Exp. Immunol. 122 (2000) 157-163
16. Ouyang Q., et al. Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes. Diabetes 55 (2006) 3068-3074
17. Husebye E.S., et al. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology 147 (2006) 2411-2416
18. Bradwell A.R., and Harvey T.C. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353 (1999) 370-373
19. Betea D., et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J. Clin. Endocrinol. Metab. 89 (2004) 3413-3420
20. Haupt K., et al. Induction of a cellular and humoral immune response against preprocalcitonin by genetic i: a potential new treatment for medullary thyroid carcinoma. Endocrinology 142 (2001) 1017-1023
21. El Hage F., et al. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10119-10124
22. Schott M., et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab. 86 (2001) 4965-4969
23. Schott M., et al. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol. Immunother. 51 (2002) 663-668
24. Papewalis C., et al. IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J. Immunol. 180 (2008) 1462-1470
25. Papewalis C., et al. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer. Clin. Cancer Res. 14 (2008) 4298-4305
26. Machens A., et al. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med. 349 (2003) 1517-1525
27. Seregni E., et al. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann. Oncol. 12 Suppl 2 (2001) S69-S72
28. Oberg K., and Stridsberg M. Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv. Exp. Med. Biol. 482 (2000) 329-337
29. Hsiao R.J., et al. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 70 (1991) 33-45
30. Vikman S., et al. Gene expression in midgut carcinoid tumors: potential targets for immunotherapy. Acta Oncol. 44 (2005) 32-40
31. Vikman S., et al. CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients. Cancer Immunol. Immunother. 57 (2008) 399-409
32. Redmond W.L., and Sherman L.A. Peripheral tolerance of CD8 T lymphocytes. Immunity 22 (2005) 275-284
33. Harashima S., et al. The dense core transmembrane vesicle protein IA-2 is a regulator of vesicle number and insulin secretion. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8704-8709
34. Shen L., et al. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen. Cancer Immunol. Immunother. 53 (2004) 391-403
35. Nukaya I., et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int. J. Cancer 80 (1999) 92-97
36. Liu K.J., et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin. Cancer Res. 10 (2004) 2645-2651
37. Eppler E., et al. Carcinoembryonic antigen (CEA) presentation and specific T cell-priming by human dendritic cells transfected with CEA-mRNA. Eur. J. Cancer 38 (2002) 184-193
38. Saha A., et al. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res. 64 (2004) 4995-5003
39. Hou Y., et al. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J. Immunol. 180 (2008) 1526-1534
40. Kosmahl M., et al. Pancreatic ductal adenocarcinomas with cystic features: neither rare nor uniform. Mod. Pathol. 18 (2005) 1157-1164
41. Kondo H., et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 28 (2008) 379-387
42. Osta W.A., et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64 (2004) 5818-5824
43. Chaudry M.A., et al. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br. J. Cancer 96 (2007) 1013-1019
44. Beuschlein F., et al. Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucleic acid expression in human adrenocortical tumors. J. Clin. Endocrinol. Metab. 83 (1998) 2585-2588
45. Ortmann D., et al. Steroidogenic acute regulatory (StAR)-directed immunotherapy protects against tumor growth of StAR-expressing Sp2-0 cells in a rodent adrenocortical carcinoma model. Endocrinology 145 (2004) 1760-1766
46. Reincke M., et al. DAX-1 expression in human adrenocortical neoplasms: implications for steroidogenesis. J. Clin. Endocrinol. Metab. 83 (1998) 2597-2600
47. Grabowski P., et al. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology 81 (2005) 1-9
48. Nakao K., et al. Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol. Rep. 16 (2006) 389-392
49. Pisarev V., et al. Full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res. 9 (2003) 6523-6533
50. Tsuruma T., et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J. Transl. Med. 6 (2008) 24
51. Andersen M.H., et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients 3. Cancer Res. 61 (2001) 5964-5968
52. Jager E., et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12198-12203
53. Maio M., et al. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J. Clin. Endocrinol. Metab. 88 (2003) 748-754
54. Coulie P.G., et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol. Rev. 188 (2002) 33-42
55. Milkovic M., et al. Expression of MAGE tumor-associated antigen in thyroid carcinomas. Endocr. Pathol. 17 (2006) 45-52
56. Fuessel S., et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 66 (2006) 811-821
57. Waeckerle-Men Y., et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol. Immunother. 55 (2006) 1524-1533
58. Slovin S.F., et al. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer Immunol. Immunother. 56 (2007) 1921-1930
59. Ferrantini M., et al. Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev. 19 (2008) 93-107
60. Spisek R., and Dhodapkar M.V. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 6 (2007) 1962-1965